The New York Mets entered the season after a busy winter reshaping the roster, and that overhaul has coincided with the worst record in the majors. Front-office leader David Stearns acknowledged on May 12, 2026 that the organization must revisit its approach to signing players who carry previous medical concerns. What began as an aggressive attempt to bolster the lineup has instead been complicated by a string of physical setbacks and a prolonged stretch of poor offensive output, leaving the club searching for answers.
In addition to injury woes, the Mets’ offense has struggled to score consistently, ranking at or near the bottom of the league in runs. The lineup has featured both veterans who have fallen short of expectations and newcomers who have yet to produce, while two young outfielders—Carson Benge and A.J. Ewing—have been pressed into regular duty despite limited experience at Triple-A. Stearns defended the decision to elevate Ewing, saying he and the staff believed the rookie could handle the jump, but he also admitted that acquiring players with known physical histories comes with a quantifiable downside.
What went wrong with the offseason plan
The blueprint that front office officials drew up during the offseason relied on a mix of established stars and high-upside additions, some of whom had checkered health records. Players such as Jorge Polanco and Luis Robert Jr. were viewed as boosts to the lineup, but both have spent time sidelined, compounding problems that were already apparent from Day 1. Stearns was candid about the balance of risk and reward, noting the club is now “feeling that risk” after multiple injuries occurred in close succession. While the organization has not moved toward trading veteran pieces, the combination of missed time and underperformance has left the roster thinner and the offense less potent than anticipated.
Injury cluster and underperformance across the roster
It is not only newcomers who have faltered. Established players including Francisco Lindor and Juan Soto have at times been unavailable or limited, and recent slumps from names like Bo Bichette, Marcus Semien, Brett Baty and Francisco Alvarez have further drained run production. Reports from local outlets offered mixed updates: there was encouraging news on Lindor and reliever A.J. Minter, but less optimism around the recoveries of Polanco and Robert Jr. A notable moment came on April 26, 2026 when Robert Jr. returned to the dugout after a tough at-bat, underscoring how injuries and form have intersected to hinder team momentum.
Front-office stance: reassess, but remain patient
Stearns has framed the situation as one that requires clear-eyed evaluation rather than dramatic, immediate changes. He stressed that the organization must “absolutely have to look at our risk assessment on injured players” to learn whether scouting and medical projections underestimated the likelihood of time missed. Despite the poor start, he reiterated that the Mets possess the talent and the clubhouse character to mount a recovery and refused to entertain replacing manager Carlos Mendoza, praising Mendoza’s handling of the clubhouse and game-day decisions.
Short-term fixes and lineup experiments
With Robert out indefinitely, the team has turned to youth in the outfield, pairing Benge and Ewing despite their abbreviated seasoning in the minors. Stearns maintained that Ewing would not have been promoted unless the organization felt he was prepared to contribute at the major-league level. In the short term, the coaching staff will test different batting orders and defensive alignments to spark offense while tracking the medical timelines for injured players. Those micro-adjustments aim to stabilize production without surrendering longer-term development for prospects.
Looking ahead: realistic expectations
Stearns acknowledged that the first quarter of the season has fallen well short of standards and that the club must address both the injury patterns and lapses in performance. Yet the front office remains committed to giving the roster time to coalesce, holding the line against knee-jerk trades involving veterans and signaling confidence in the team’s capability to rebound. The coming weeks will be a test of whether adjustments in player usage, a return to health for key contributors, and opportunities for rookies can collectively lift an offense that has struggled to find consistency.
Ultimately, the Mets face a crossroads where medical prudence, player development and short-term competitiveness must be balanced. Stearns’ comments on May 12, 2026 made clear that internal review is underway, and the organization will reassess how they factor preexisting injuries into roster-building decisions going forward. For fans and evaluators, the question is whether the mix of optimism and caution at the front office will be enough to turn a disappointing start into a viable midseason push.
